Purpose: Reducing drug spend is one of the greatest challenges for practices participating in the Oncology Care Model (OCM). Evidence-based clinical pathways have the potential to decrease drug spend while maintaining clinical outcomes consistent with published evidence. The goal of this study was to determine whether voluntary use of clinical pathways by a practice can maximize OCM episodic cost savings.
Methods And Materials: A community oncology practice used evidence-based clinical pathways for OCM-attributed patients. All treatment plans were submitted to the pathway vendor in real time for clinical pathway adherence measurement. Analysis was conducted before implementation and on an ongoing daily and weekly basis to identify cases in which higher cost drugs or regimens were ordered. A clinical data governance committee met biweekly to review clinical pathway performance metrics and drug utilization.
Results: From quarter 1 of 2017 to quarter 1 of 2019, the median drug spend increased less rapidly for Cancer Care Specialists of Illinois (CCSI; 18.6%) compared with OCM (34.4%). Furthermore, the percent difference in drug spend for CCSI relative to OCM decreased from 13.5% to 0.1% ( < .001). Each quarter, there was approximately a 1.7% decrease (95% CI, 1.0% to 2.4%) in drug spend for CCSI relative to OCM. Additional analyses found that, over a 15-month period (October 2017 through December 2019), CCSI achieved an increase in pathway adherence from 69% to 81%.
Conclusion: Reduction in drug spend is possible within a value-based care model, using evidence-based clinical pathways.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224689 | PMC |
| http://dx.doi.org/10.1200/JOP.19.00753 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrating Analytical Procedures in Routine Practices of Centralized Antiblastic Compounding Units for Valorization of Residual Compounded Drugs.
Pharmaceutics
January 2025
Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.
Background/objectives: Although extemporaneous formulations of anticancer drug products for personalized therapy are produced according to Good Hospital Pharmacy Manufacturing Practice, the lack of knowledge about drug stability under clinical conditions limits the second-time use of these highly costly medications in clinical practice. Therefore, the residual compounded drugs are considered waste and a cost item that negatively affects the healthcare system. In the context of the ever-increasing interest of the health system in applying practices in line with personalized medicine and spending review policies, this research aimed to demonstrate the feasibility of incorporating analytical techniques into daily routine practice.
View Article and Find Full Text PDFPricing for Multi-Indication Drugs in the Italian Regulatory Context.
Pharmacoecon Open
January 2025
HTA & Pharmaceutical Economics Department, Italian Medicines Agency (AIFA), Rome, Italy.
Background: The authorization of new therapeutic indications for drugs already reimbursed by the Italian National Health Service (NHS) represents a matter of importance. This study aims to estimate the additional discount attributed to the extension of indications (EoIs) to explore the potential correlation between spending and negotiated discounts and to find specific factors (determinants) that impact on discount.
Methods: The study focused on drugs approved in Italy between 2003 and 2017 with at least four therapeutic indications, including the first approved and EoIs, with follow-up extended until 2021 to acquire all the information on the negotiation process that has been completed.
The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM).
J Natl Cancer Inst
January 2025
MD Anderson Cancer Center, Houston, TX, USA.
It has long been assumed that academic oncology practices are disadvantaged in value-based payment programs, due to patient complexity and research costs. This assumption not been tested. The Oncology Care Model (OCM) was a Medicare alternative payment model, which sought to curb costs while improving care.
View Article and Find Full Text PDFSpatial Accessibility Analysis of Snake Antivenom.
Int J Public Health
January 2025
School of Public Health, Hainan Medical University, Haikou, Hainan Province, China.
Objectives: To analyze the spatial accessibility of antivenom immunizing agents equipped hospitals in Hainan Province.
Methods: This paper analyzes the spatial accessibility of medical institutions equipped with different types of snake antivenom using network analysis and two-step mobile search method, and evaluates the service level and spatial accessibility of medical institutions equipped with different types of antivenom immunizing agents in Hainan Province from the perspectives of both supply and demand.
Results: The number of people in Hainan Province who need to spend more than 1 h to reach an antivenom, antivenom, antivenom, antivenom equipped hospital, and equipped with antivenom for all species of snakes in the country is approximately 856,000, 231,300, 3,071,000, 2,666,000 and 4,721,000 people, respectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!